Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Shivani K. Patel"'
Autor:
Mark Linzer, Sanjoyita Mallick, Purva Shah, Anne Becker, Nancy Nankivil, Sara Poplau, Shivani K. Patel, Caitlin Nosal, Christine A. Sinsky, Elizabeth Goelz, Martin Stillman, Michaella Alexandrou, Erin E. Sullivan, Roger Brown
Publikováno v:
BMC Medical Education, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background System contributors to resident burnout and well-being have been under-studied. We sought to determine factors associated with resident burnout and identify at risk groups. Methods We performed a US national survey between July 15
Externí odkaz:
https://doaj.org/article/5f208ade662345bb8805bae8d0b78523
Publikováno v:
Diabetic Medicine. 38
We commend Foteinopoulou and colleagues on their efforts to determine the impact of random serum C-peptide measurements on diagnosis and treatment in clinically diagnosed type 1 diabetes (T1D) individuals. We agree that there is a role for the incorp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e1c9d88f0e03ec7487b53843a912c89
https://doi.org/10.1111/dme.14513
https://doi.org/10.1111/dme.14513
Publikováno v:
Trends in endocrinology and metabolism: TEM. 32(5)
Up to 15% of individuals with a clinical phenotype of type 1 diabetes (T1D) do not have evidence of seropositivity for pancreatic islet autoantibodies. On this basis, they are classified as nonimmune or idiopathic, and remain an understudied populati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7849ade89f7fda460f7b55c84c998c9c
https://pubmed.ncbi.nlm.nih.gov/33712367
https://pubmed.ncbi.nlm.nih.gov/33712367
Autor:
Vipul Patel, Shivani K. Patel
Publikováno v:
International Journal of Engineering Research and.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85d30fe00778db7fe2404d6da3d70237
https://doi.org/10.17577/ijertv9is050808
https://doi.org/10.17577/ijertv9is050808
Publikováno v:
International Journal of Engineering Research and.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f8087c453ffd4135aa2563782263217
https://doi.org/10.17577/ijertv9is050780
https://doi.org/10.17577/ijertv9is050780
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-5 (2019)
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-5 (2019)
Summary Durvalumab is a programmed cell death ligand 1 inhibitor, which is now approved in Australia for use in non-small-cell lung and urothelial cancers. Autoimmune diabetes is a rare immune-related adverse effect associated with the use of immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84e545cf0f4611fde49e8fe351f93f02
http://europepmc.org/articles/PMC6935712
http://europepmc.org/articles/PMC6935712